Key Spec Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|A||IP, WB||M||Purified||Monoclonal Antibody|
|Description||Anti-acetyl-Lysine Antibody, clone 4G12|
|Presentation||1mg of protein G purified mouse IgG in 0.75 mL of PBS.|
|Application||Anti-acetyl-Lysine Antibody, clone 4G12 is a high quality Mouse Monoclonal Antibody for the detection of acetyl-Lysine & has been validated in IP & WB.|
|Safety Information according to GHS|
|Storage and Shipping Information|
|Storage Conditions||2 years at -20°C|
|Material Size||1 mg|
|Anti-Acetyl-Lysine, clone 4G12 - 26626||26626|
|Anti-Acetyl-Lysine, clone 4G12 - 29636||29636|
|Anti-Acetyl-Lysine, clone 4G12 - 31383||31383|
|Anti-acetyl-Lysine, clone 4G12 (mouse monoclonal IgG) - 2080304||2080304|
|Reference overview||Pub Med ID|
|p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage.|
Liu, L, et al.
Mol. Cell. Biol., 19: 1202-9 (1999) 1999
The p53 tumor suppressor protein is a sequence-specific transcription factor that modulates the response of cells to DNA damage. Recent studies suggest that full transcriptional activity of p53 requires the coactivators CREB binding protein (CBP)/p300 and PCAF. These coactivators interact with each other, and both possess intrinsic histone acetyltransferase activity. Furthermore, p300 acetylates p53 to activate its sequence-specific DNA binding activity in vitro. In this study, we demonstrate that PCAF also acetylates p53 in vitro at a lysine residue distinct from that acetylated by p300 and thereby increases p53's ability to bind to its cognate DNA site. We have generated antibodies to acetylated p53 peptides at either of the two lysine residues that are targeted by PCAF or p300 and have demonstrated that these antibodies are highly specific for both acetylation and the particular site. Using these antibodies, we detect acetylation of these sites in vivo, and interestingly, acetylation at both sites increases in response to DNA-damaging agents. These data indicate that site-specific acetylation of p53 increases under physiological conditions that activate p53 and identify CBP/p300 and PCAF as the probable enzymes that modify p53 in vivo.
|Acetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome.|
Munshi, N, et al.
Mol. Cell, 2: 457-67 (1998) 1998
The transcriptional coactivators CBP and P/CAF are required for activation of transcription from the IFN beta enhanceosome. We show that CBP and P/CAF acetylate HMG I(Y), the essential architectural component required for enhanceosome assembly, at distinct lysine residues, causing distinct effects on transcription. Thus, in the context of the enhanceosome, acetylation of HMG I by CBP, but not by P/CAF, leads to enhanceosome destabilization and disassembly. We demonstrate that acetylation of HMG I(Y) by CBP is essential for turning off IFN beta gene expression. Finally, we show that the acetyltransferase activities of CBP and P/CAF modulate both the strength of the transcriptional response and the kinetics of virus-dependent activation of the IFN beta gene.
|Acetylation of general transcription factors by histone acetyltransferases.|
Imhof, A, et al.
Curr. Biol., 7: 689-92 (1997) 1997